Drug pricing

News

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

Market Access

Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.

News

Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that.

Market Access

Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.

News

AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

News

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.